We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Acer Therapeutics

News List

Acer Therapeutics Plans Clinical Trial for Edsivo (celiprolol) Following Type B FDA Meeting drugs
June 21, 2021
Acer Therapeutics Inc. today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA) regarding Acer’s proposed Edsivo™ (celiprolol) development plan
Acer Therapeutics, NCATS partner to develop emetine for Covid-19 pharmaceutical-technology
May 14, 2020
Pharmaceutical company Acer Therapeutics has partnered with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride for the potential treatment of Covid-19 patients.
Sanofi offloads drug programmes to MyoKardia and Acer Therapeutics pharmaceutical-technology
January 04, 2019
Sanofi has returned worldwide rights to all programmes that were covered under a licence and collaboration agreement signed with biopharmaceutical company MyoKardia in 2014.